Our discovery of dominant-negative inhibition of prion formation in cultured cells provided an explanation for the resistance of some sheep to scrapie and humans to Creutzfeldt-Jakob disease. To determine whether dominant-negative inhibition occurs in vivo, we produced transgenic (Tg) mice expressing prion protein (PrP) with either the Q167R or Q218K mutation alone or in combination with wild-type (wt) PrP. Tg(MoPrP,Q167R)Prnp 0/0 mice expressing mutant PrP at levels equal to non-Tg mice remained healthy for >550 days, indicating that inoculation with prions did not cause disease. Immunoblots of brain homogenates and histologic analysis did not reveal abnormalities. Tg(MoPrP,Q167R)Prnp ؉/؉ mice expressing both mutant and wt PrP did not exhibit neurologic dysfunction, but their brains revealed low levels of the PrP pathogenic isoform (PrP Sc ), and sections showed numerous vacuoles and severe astrocytic gliosis at 300 days after inoculation. Both Tg(MoPrP,Q218K)Prnp 0/0 and Tg(MoPrP,Q218K)Prnp ؉/؉ mice expressing high levels of the transgene product remained healthy for >300 days after inoculation. Neither PrP Sc nor neuropathologic changes were found. Our studies demonstrate that although dominant-negative inhibition of wt PrP Sc formation occurs, expression of the dominant-negative PrP at the same level as wt PrP does not prevent prion formation completely. However, expression of dominant-negative PrP alone had no deleterious effects on the mice and did not support prion propagation.
I
n prion diseases, the aberrantly folded isoform (PrP Sc ) of the normal, cellular prion protein (PrP C ) stimulates the conversion of PrP C into nascent PrP Sc . The accumulation of PrP Sc leads to CNS dysfunction and neuronal degeneration (1) . At present, there is no accepted therapy for prion diseases, and whether the drug quinacrine will prove to be effective in treating these diseases remains to be established (2) . In addition to quinacrine (3), other compounds that block prion replication as well as stimulate the clearance of existing prions include branched polyamines (4), phthalocyanines and porphyrin derivatives (5) , Congo red (6) , compound 60 (7), ␤-breaker peptides (8) , and anti-PrP antibodies (9, 10) . Although many of the foregoing compounds are able to clear prions in scrapie-infected neuroblastoma cells, none have been shown to be effective in animals or humans to date (11) . It is noteworthy that both vaccination and passive immunization have effectively decreased A␤ amyloid deposits in the brains of transgenic (Tg) mice expressing mutant amyloid precursor protein (12) (13) (14) . Unfortunately, some attempts to vaccinate humans with A␤ have resulted in an allergic meningoencephalitis, which halted a clinical trial (15) .
One compound noted above was designed to mimic dominantnegative inhibition of prion replication (7) . Dominant-negative inhibition occurs when the product of the mutant or variant allele interferes with a function of the wild-type (wt) allelic protein.
Naturally occurring polymorphic variants of PrP, Q171R and E219K, known to render sheep and humans resistant to scrapie and Creutzfeldt-Jakob disease, respectively (16) (17) (18) , were found to act as dominant negatives in scrapie-infected neuroblastoma cells (19, 20) .
Based on these findings, we undertook studies on dominantnegative PrP. Tg mice expressing mutant PrP with either Q167R or Q218K or coexpressing mutant and wt PrP were inoculated with Rocky Mountain Laboratory (RML) prions, and incubation times were determined. We found that expression of dominant-negative PrP at the same level as wt PrP dramatically slowed PrP Sc formation. Moreover, dominant-negative PrP was not converted into PrP Sc , and its expression, even at high levels, had no deleterious effects on the mice.
Materials and Methods
Nomenclature. Residue 171 in sheep PrP corresponds to codon 167 in mouse PrP (MoPrP) and codon 168 in human PrP (HuPrP). Residue 219 in HuPrP corresponds to codon 218 in MoPrP.
Laboratory Animals and Inoculum. We obtained wt FVB mice from Charles River Breeding Laboratories. Tg(MoPrP-A)4053 mice have been described (21) . MoPrP,Q167R and MoPrP,Q218K mutant genes were subcloned into the cosTet vector for microinjection (19) . Tg(MoPrP,Q167R)Prnp mice, respectively, with FVB mice until we obtained the third (F 3 ) generation. In these mice, both the transgene and wt Prnp genes were identified by PCR screening.
The RML prion inoculum was as described (22) .
coupled to gauge needles of decreasing diameters and by repeated suctions and extrusions of the solution. After the solution was centrifuged for 5 min at 2,000 rpm in a Beckman centrifuge, the supernatant was collected. Protein concentration was measured with the bicinchoninic acid reagent (BCA, Pierce) and corresponds to 10 mg͞ml. Volumes (500 l) of 1% homogenates were prepared in PBS and 2% Sarkosyl and digested with 20 g͞ml of proteinase K (PK) at a ratio of 1:50 (PK͞protein) for 1 h at 37°C. The digestion was stopped with 5 mM phenylmethylsulfonyl fluoride. PK-treated samples were mixed with an equal volume of SDS-loading buffer and boiled for 5 min, and 30 l were loaded on 12% SDS͞PAGE precast gels (Bio-Rad). Undigested samples were prepared by mixing an aliquot of 10% homogenate with an equal volume of SDS-loading buffer and then boiled for 5 min. Prepared samples (10 l) were loaded on 12% SDS͞PAGE precast gels. Immunoblot analysis was performed according to a protocol described previously (28) .
Quantification of PrP Sc by Conformation-Dependent Immunoassay (CDI). To detect levels of PrP

Sc
, an immunoassay was performed on Syrian hamster PrP according to a technique described previously (29) .
Preparation of the Calibration Curve. Brains from normal or RMLinoculated FVB mice were resuspended to 5% solution, in PBS and 2% Sarkosyl, as described above. Fivefold serial dilutions were performed by diluting the 5% RML-FVB brain homogenate with 5% normal FVB brain homogenate. Ten-point dilutions were completed starting at 1% and continuing with 0.2, 0.04, 0.008%, etc. Then, 1-ml aliquots were digested with 25 g͞ml PK at a 1:200 ratio (PK͞protein) for 1 h at 37°C on a shaker. The reaction was stopped by a mixture of protease inhibitors; samples were precipitated with sodium phosphotungstate and processed as described in ref. 29 . The samples were quantified by CDI using time-resolved fluorescence spectroscopy (29) . The europium-labeled HuM-D13 Fab was used to detect mutant and wt MoPrP.
Preparation of Modified MoPrP. The 10% brain homogenates previously analyzed by immunoblots were tested also by CDI. Homogenates were diluted to 5% solution in PBS͞2% Sarkosyl and rehomogenized with a syringe to break aggregates. Aliquots of 1 ml were digested with 25 g͞ml PK for 1 h at 37°C on a shaker. The samples were processed as described above.
Neuropathology. Brain tissue was immersion-fixed in 10% buffered formalin immediately after the mice were killed. Histological sections were prepared and stained with hematoxylin͞eosin as described (30) .
Histoblots. Histoblots were performed as described in ref. 31 . mice that remained healthy were killed for immunoblot analysis to determine the level of PrP transgene expression (Fig.  1a) . Equal amounts of protein were loaded on the gel as judged by immunoblotting of glyceraldehyde 3-phosphate dehydrogenase.
Results
RML Prions in
Brain homogenates from FVB mice inoculated with RML prions were subjected to limited proteolysis; these samples gave a strong protease-resistant PrP Sc signal (Fig. 1b, lane 11) . PK-digested samples from inoculated Tg(MoPrP,Q167R)Prnp 0/0 (Fig. 1b, lanes *Expression levels were determined by comparing serial dilutions of Tg mouse brain homogenates to that of normal FVB mice (1 ϫ PrP level) by immunoblot. † n, number of sick mice; n0, number of inoculated mice. ‡ Seven animals died atypically of prolapsus at the mean incubation time indicated; three healthy animals were killed at 300 days for Western blot and histoblot analyses. Because the Q167R mutation might render PrP Sc more sensitive to PK-catalyzed hydrolysis, we digested the samples with PK concentrations ranging from 1 to 20 g͞ml (Fig. 1c) . Brains from FVB mice inoculated with RML prions showed an increased PrP Sc signal with lower PK concentrations; however, no PrP Sc band was present in the brain extracts of both inoculated and uninoculated Tg(MoPrP,Q167R)Prnp 0/0 mice even at 1 g͞ml PK. Based on these immunoblots and the lack of neuropathology in Tg(MoPrP,Q167R)Prnp 0/0 mice, we conclude that MoPrP(Q167R) is unable to support PrP Sc formation.
None of the 10 Tg(MoPrP,Q167R)Prnp ϩ/ϩ mice, which express same levels of both wt and mutant MoPrP, showed signs of CNS dysfunction more than 400 days after inoculation with prions (Table  1) . To determine whether wt MoPrP C in Tg(MoPrP,Q167R)-Prnp ϩ/ϩ mice supported prion replication, we killed two apparently healthy Tg(MoPrP,Q167R)Prnp ϩ/ϩ mice 300 days after inoculation and performed immunoblot analysis (Fig. 2) . PK-digested homogenates revealed the presence of low amounts of protease-resistant PrP, with similar intensity (Fig. 2b, lanes 1 and 2) . The intensity of these bands corresponds to Ϸ10% of the signal obtained with FVB mice inoculated with prions (Fig. 2b, lane 10) , arguing for a diminished rate of PrP Sc formation. The remaining seven inoculated Tg(MoPrP,Q167R)Prnp ϩ/ϩ mice presented atypical neurologic signs with a mean incubation time of 447 Ϯ 11 days. Because we detected some wt PrP Sc replication in the brains of these mice at 300 days, it seems likely that further prion replication occurred over the subsequent 150 days. The additional presumed replication of prions and neuropathology described below argue that these mice died of prion disease, but the cause of death remains to be established.
Neuropathology of Tg(MoPrP,Q167R) Mice. Pathological studies were performed on the midbrains of the Tg(MoPrP,Q167R) mice analyzed by immunoblotting ( Figs. 1 and 2 ). Both inoculated and uninoculated Tg(MoPrP,Q167R)Prnp 0/0 mice showed no vacuolation in the hippocampus (Fig. 5 e and g, which is published as supporting information on the PNAS web site, www.pnas.org) but showed minimal astrocytic gliosis, which is consistent with aging (compare with Fig. 5 f and h) .
In contrast, hippocampal sections from Tg(MoPrP,Q167R)-Prnp ϩ/ϩ mice revealed widespread vacuolation associated with severe astrocytic gliosis at 300 days after inoculation (Fig. 5 i and j) . The severity of the neuropathologic changes resembled that of prion-inoculated FVB mice (Fig. 5 a and b) . However, neurodegeneration was localized in the ventral hippocampus in Tg(MoPrP,Q167R)Prnp ϩ/ϩ mice, whereas both the ventral and dorsal hippocampus of FVB mice were affected, with the most intense changes in the dorsal area. Histopathologic analyses of uninoculated Tg(MoPrP,Q167R)Prnp ϩ/ϩ mice ( Fig. 5 k and l) resembled those of uninoculated FVB mice (Fig. 5 c and d) . Our findings show an excellent correlation between Western blot and neuropathological analysis; the presence of PrP Sc was accompanied by vacuolation and astrocytic gliosis. To establish a calibration curve for MoPrP Sc , brain homogenates were prepared from FVB mice infected with RML prions (Fig. 3a) . A linear relationship between PrP Sc level and a brain dilution up to 3.2 ϫ 10 Ϫ5 was demonstrated. Whether MoPrP Sc was detected after a dilution of 10 Ϫ6 , which corresponds to a D͞N ratio of 1.25 Ϯ 0.04, is unclear. Control brain homogenates from uninoculated FVB mice gave a D͞N ratio of 1.1 Ϯ 0.04 (Fig. 3b ) in contrast to a value of 1.67 for Syrian hamster brains (29) .
Brain homogenates (1%, wt͞vol) prepared from RMLinoculated FVB mice gave a D͞N ratio of 82 Ϯ 2.3. We prepared 5% brain homogenates from Tg mice to detect potential traces of PrP Sc . Using the CDI, we detected PrP Sc only in homogenates from RML-inoculated Tg(MoPrP,Q167R)Prnp ϩ/ϩ mice, with samples from two animals giving D͞N ratios of 46 Ϯ 1.5 and 45 Ϯ 1.6 (Fig.  3b) , which correspond to 0.05 g͞ml PrP (Fig. 2b, lanes 1  and 2) and histoblots (Fig. 6e) days. It is likely that these animals developed a spontaneous disease because 6 of 10 uninoculated mice also died with a mean survival time of 442 Ϯ 49 days (Table 2 ). This result is not surprising because of the high expression level (32ϫ) of the transgene; high levels of PrP expression have been reported to cause disease (32) .
Similar results were obtained with Tg(MoPrP,Q218K)20250͞ Prnp 0/0 mice, which express mutant PrP at 32ϫ level. All inoculated mice developed CNS dysfunction after 315 Ϯ 33 days, whereas uninoculated mice showed clinical signs after 322 Ϯ 30 days. Neuropathological examination revealed numerous vacuoles and pronounced astrocytic gliosis in both inoculated and uninoculated animals, and neither group had PrP Sc based on immunoblots (data not shown). These findings argue that Tg(MoPrP,Q218K)22500͞ Prnp 0/0 mice develop spontaneous neurologic disease but are resistant to infection by RML prions.
Five of eight Tg(MoPrP,Q218K)22500͞Prnp ϩ/ϩ mice inoculated with prions became ill, with a mean incubation time of 374 Ϯ 24 days. It is possible that these mice also developed spontaneous neurodegeneration because noninoculated controls became ill, with one animal dying at 319 days and two mice still living but presenting signs of ataxia at 370 days ( Table 2) .
In contrast, Tg(MoPrP,Q218K)21603͞Prnp 0/0 mice that express lower levels of PrP did not develop spontaneous disease. None of the 18 inoculated Tg(MoPrP,Q218K)21603͞Prnp 0/0 mice showed signs of disease after more than 468 and 550 days, which is remarkable because of the 16ϫ expression level. (Table 2) . Currently, two Tg(MoPrP,Q218K)21603͞Prnp ϩ/ϩ mice remain healthy after 508 days, as is true for all uninoculated mice from this Tg line (Table 2) .
Immunoblots of Tg(MoPrP,Q218K) Mice. To distinguish between neurodegeneration caused by prions and that caused by misprocessing of the transgene product, we performed immunoblotting on brain homogenates of Tg(MoPrP,Q218K)22500͞Prnp 0/0 and Tg(MoPrP,Q218K)21603͞Prnp 0/0 mice. We were interested in whether Tg(MoPrP,Q218K)22500͞Prnp ϩ/ϩ and Tg(MoPrP, Q218K)21603͞Prnp ϩ/ϩ mice were able to form nascent wt PrP Sc as seen in Tg(MoPrP,Q167R)Prnp ϩ/ϩ mice. For each experimental group in Table 2 , two animals were killed when they were young, and immunoblots were performed on their brain homogenates before and after PK digestion (Fig. 4 a and b) . None of the samples from young mice with the Prnp
background showed detectable levels of PrP Sc regardless of whether the animals were inoculated with RML prions (Fig. 4b ). These samples were tested by CDI, and resulting D͞N ratios were always below the 1.67 cut-off value for PrP Sc (data not shown). Additional samples from Tg mice were taken between 319 and 552 days after inoculation for analysis. Protease-digested brain homogenates from ill Tg(MoPrP, Q218K)21603͞Prnp ϩ/ϩ mice revealed low amounts of PrP Sc (Fig.  4c, lanes 13 and 14) , whereas PK-digested samples from ill Tg(MoPrP,Q218K)22500͞Prnp ϩ/ϩ mice did not (Fig. 4c, lanes 5  and 6) .
From these findings, we conclude that inoculated Tg(MoPrP,Q218K)22500͞Prnp mice is unknown. One argument is that these mice died of brain degeneration caused by the accumulation of the transgene product, but none of the other Tg(MoPrP,Q218K)21603 mice developed CNS illness (Table 2) . Alternatively, relatively low levels of PrP 
Discussion
The discovery of dominant-negative inhibition of prion replication began with the finding that chimeric HuM PrP transgenes rendered mice susceptible to human prions (33, 34) . Using scrapie-infected neuroblastoma cells, we mapped the residues on PrP C that are critical for dominant-negative inhibition of prion replication (19) . The side chains of these residues on the surface of PrP C form a discontinuous epitope near the C terminus, which is thought to bind to a macromolecule provisionally designated protein X. The avid binding of dominant-negative PrP to protein X is presumed to result in the sequestering of the protein, which in turn prevents conversion of wt PrP C into PrP Sc . Scrapie-infected neuroblastoma-cell studies and investigations of naturally occurring PrP polymorphisms in sheep and humans that protect them from prion diseases argued for dominant-negative inhibition of prion replication. Although these polymorphisms may be more effective in the context of the ovine or human sequence, we postulated that experimental testing of this hypothesis in Tg mice would allow better characterization of the protective effects of dominant-negative variants. We produced mice expressing mutant MoPrP transgenes that carry either polymorphic residue protecting sheep or humans. The substitution of arginine at codon 167 or lysine at 218 rendered MoPrP C unconvertible into PrP Sc . When the transgene product and wt MoPrP C were coexpressed, prion formation was retarded.
Dominant-Negative Inhibition of Scrapie. At codon 171, both heterozygous Q͞R and homozygous R͞R Suffolk sheep were found to be resistant to natural scrapie (17) . In studies of experimental scrapie, Cheviot sheep carrying Q͞R or R͞R at residue 171 were found to be resistant to prion infection (16, (35) (36) (37) . Similar findings have been reported for flocks of Texel sheep with natural scrapie. Sheep expressing ARR͞ARR or ARR͞AHQ at positions 136, 154, and 171, respectively, were the most resistant to scrapie, with 89% of animals surviving; sheep expressing VRQ͞VRQ, ARQ͞VRQ, or ARH͞VRQ were the most susceptible to disease, with only 5% unaffected (38, 39) . These findings are readily explained by our results with Tg(MoPrP,Q167R)Prnp ϩ/ϩ mice; position 167 in MoPrP corresponds to 171 in sheep PrP. Therefore, we conclude that protection of sheep expressing Q͞R at position 171 from scrapie is caused by dominant-negative inhibition. Sheep expressing R͞R at 171 were protected also because MoPrP(Q167R) was not converted into PrP Sc even after 500 days after prion inoculation.
Dominant-Negative Inhibition of Prion Disease in Humans.
Among the Japanese population, 12% carry the E͞K polymorphism at position 219, whereas remaining individuals are E͞E. None of 85 autopsied sporadic Creutzfeldt-Jakob disease cases were found to be E͞K, suggesting that heterozygosity at 219 protects humans from this disease (40, 41) . These findings are readily explained by our results with Tg(MoPrP,Q218K)Prnp ϩ/ϩ mice; position 218 in MoPrP corresponds to 219 in HuPrP. Thus, protection of humans expressing E͞K at codon 219 from Creutzfeldt-Jakob disease is caused by dominant-negative inhibition.
Transgene Expressions Levels and Dominant-Negative Inhibition. In planning the studies described here, we sought to produce one mouse line with relatively low levels of mutant PrP expression and at least one line with high levels of mutant PrP expression. Tg (Table 2) .
Although Tg(MoPrP,Q167R)Prnp ϩ/ϩ mice were asymptomatic at 300 days after inoculation with RML prions, their brains contained detectable levels of PrP Sc (Figs. 2 and 3) . Presumably, PrP (Fig. 4c) .
Prevention of Prion Disease. The inability of MoPrP(Q167R) and MoPrP(Q218K) to support prion replication raises the possibility of producing prion-resistant livestock that express PrP with a single amino acid substitution. Because sheep homozygous for R at position 171 already exist, breeding populations of resistant sheep is a reasonable undertaking. Presumably, this was the genetic basis of Parry's scrapie eradication program in Great Britain 40 years ago (42, 43) . However, this natural protection might be restricted to certain prion strains. Recently, experimental transmission of bovine spongiform encephalopathy prions to sheep showed that animals carrying ARQ͞ARQ at codon 136, 154, and 171, respectively, died after 672 days, whereas sheep harboring ARR͞ARR were resistant to bovine spongiform encephalopathy prions (44) . The ARR͞ARR sheep showed neither neurologic signs nor PrP Sc deposits in their brains. It would seem prudent to explore the utility of such an approach by inoculating Tg(ShePrP,Q171R)Prnp mice with many different prion strains, might be useful in evaluating the utility of producing prion-resistant cattle. Although the introduction of a point mutation may not produce complete resistance to prion infection as disruption of the Prnp gene does (45, 46) , it may prove to be more desirable. Whether disruption of the Prnp gene produces some subtle but important aberration in cattle, sheep, or pigs is unknown; moreover, such livestock may be considered unacceptable to consumers. In contrast, the introduction of a naturally occurring point mutation may be less detrimental biologically and accepted more readily by consumers. Both germ-line and somatic cell gene therapy strategies could be applied in principle.
Should single point mutations in sheep or bovine PrP transgenes prove to be ineffective with some strains, it may be prudent to construct a transgene carrying both substitutions. Whether Tg mice expressing BoPrP(Q179R,Q230K) will be healthy or develop spontaneous neurodegeneration is unknown (32) . Moreover, whether such mice will be more resistant to prion disease remains to be established.
